Denali Therapeutics (DNLI) Accounts Payables (2017 - 2026)
Denali Therapeutics (DNLI) reported Accounts Payables of $40.4 million for Q1 2026, up 377.42% year-over-year from $8.5 million in Q1 2025, and up 7896.04% on a QoQ basis from $505000.0 in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Accounts Payables data on file, last reported at $40.4 million in Q1 2026.
- Quarterly Accounts Payables rose 377.42% year-over-year to $40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.4 million (up 377.42% YoY) and the FY2025 annual result came in at $505000.0, down 95.47% from the prior year.
- Accounts Payables grew to $40.4 million in Q1 2026 per DNLI's latest filing, from $505000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $40.4 million in Q1 2026 and bottomed at $505000.0 in Q4 2025.
- The 5-year median for Accounts Payables is $8.5 million (2025), against an average of $9.6 million.
- The widest annual swing landed in 2024, when Accounts Payables jumped 435.21%; it then tumbled 95.47% in 2025.
- Tracing DNLI's Accounts Payables over 5 years: stood at $2.8 million in 2022, then surged by 239.89% to $9.5 million in 2023, then advanced by 17.44% to $11.1 million in 2024, then plunged by 95.47% to $505000.0 in 2025, then soared by 7896.04% to $40.4 million in 2026.
- Per Business Quant, the three latest DNLI Accounts Payables figures stand at $40.4 million (Q1 2026), $505000.0 (Q4 2025), and $6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | 40.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.38 Mn |
| Dec 31, 2025 | 505,000.00 |
| Sep 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 10.84 Mn |
| Mar 31, 2025 | 8.46 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 9.59 Mn |
| Jun 30, 2024 | 13.94 Mn |
| Mar 31, 2024 | 11.86 Mn |
| Dec 31, 2023 | 9.48 Mn |
| Sep 30, 2023 | 10.40 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 2.79 Mn |
| Sep 30, 2022 | 7.54 Mn |
| Jun 30, 2022 | 7.12 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 4.78 Mn |
| Sep 30, 2021 | 4.82 Mn |
| Jun 30, 2021 | 4.24 Mn |
| Mar 31, 2021 | 1.63 Mn |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 2.81 Mn |
| Jun 30, 2020 | 1.87 Mn |
| Mar 31, 2020 | 2.32 Mn |
| Dec 31, 2019 | 2.59 Mn |
| Sep 30, 2019 | 2.02 Mn |
| Jun 30, 2019 | 3.93 Mn |
| Mar 31, 2019 | 3.66 Mn |
| Dec 31, 2018 | 1.89 Mn |
| Sep 30, 2018 | 3.35 Mn |
| Jun 30, 2018 | 9.18 Mn |
| Mar 31, 2018 | 1.38 Mn |
| Dec 31, 2017 | 2.72 Mn |